The Partners in Bleeding Disorders Education Program recently launched “Clinical Management of Inhibitors Module 3: Immune Tolerance Induction (ITI),” the purpose of which is to sharpen clinical knowledge and skills relating to the nursing role in eradication of inhibitory antibodies to factor VIII and IX via ITI therapy.

This module, which is available until 5:00pm Eastern Time, July 19, 2018, is intended specifically for nursing professionals and other healthcare providers at hemophilia treatment centers (HTCs) who are involved in the management of individuals with congenital hemophilia who have inhibitors.

This activity is provided for 0.75 contact hours under American Nurses Credentialing Center (ANCC) criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

Established in 1996, the Partners Program promotes excellence in care through education created by and for the federally recognized HTC Network and providers from a variety of disciplines that serve patients with bleeding and other coagulation disorders. The program is a collaborative initiative of the Indiana Hemophilia & Thrombosis Center, NHF, and the Hemophilia Foundation of Michigan. Funding to support the Partners in Bleeding Disorders Education Program is provided through an unrestricted educational grant from Shire.

Learn more about “Clinical Management of Inhibitors Module 3: Immune Tolerance Induction (ITI)” and other online educational activities by going to the PartnersPRN web site.